Dr. Rahul R. Aggarwal, MD

Dr. Aggarwal practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Aggarwal's NPI, 1174794309, was assigned on March 15, 2008. Dr. Aggarwal graduated from Feinberg School of Medicine in 2006. Dr. Aggarwal's California license number on file is A102876.

Dr. Aggarwal's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Aggarwal's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Aggarwal to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Aggarwal practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Aggarwal's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Aggarwal is board certified in hematology by the American Board of Internal Medicine. Dr. Aggarwal has a license on file in California.

Dmand AI lists chronic leukemia, fluid and electrolyte imbalances and prostate cancer among the conditions Dr. Aggarwal treats.

CMS data shows 862 Medicare services from Dr. Aggarwal across 9 procedure codes in 2024, for 246 Medicare patients. Medicare paid $65,930 for them.

CMS counts 246 Medicare patients who saw Dr. Aggarwal in 2024. The largest group is 75 to 84, with 114 patients. 75% of them have cancer, and 68% have high blood pressure. 9% are also on Medicaid. Their average risk score is 2.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Aggarwal's median patient age at 73, with 14% women.

In 2024, Dr. Aggarwal wrote 332 Medicare Part D claims for 76 patients. 60% of them were for generic drugs. CMS names the drug for 196 of them, across 6 drugs with 11 or more claims each, at $1,091,192 in total drug cost. In 2023, CMS named 369 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Aggarwal for performance year 2024, reported as part of a group. Dr. Aggarwal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Aggarwal as offering telehealth.

Laminectomy or laminotomy (partial removal of spine bones): 1 to 10 procedures (CMS shows small counts as a range)

Spinal fusion: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 112 papers to Dr. Aggarwal, published from 2011 to 2025. 2021 was the busiest year, with 14. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Prostate-Specific Antigen. Dr. Aggarwal has published most often in Clin Cancer Res. Dr. Aggarwal's most frequent co-authors are Eric J. Small, MD, Terence Ware Friedlander, MS and Jonathan Chou, MD, PhD.

Dmand AI links Dr. Aggarwal to 11 clinical trials, 5 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. University of California, San Francisco sponsors the most, 4.

CMS Open Payments shows 104 general payments to Dr. Aggarwal from 18 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 82% of the total. Merck Sharp & Dohme Corporation paid the most, $36,294. It also lists 2 research payments totaling $5,659 from 2024 to 2025.

Dmand AI lists 1 award for Dr. Aggarwal, most recently CMS Stage 1 EHR in 2013.

Dr. Aggarwal graduated from Feinberg School of Medicine in 2006.

Dr. Aggarwal is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.